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Blurring the boundary between innate and adaptive immune system, natural killer (NK) cells
are widely recognized as potent anti-leukemia mediators. Alloreactive donor NK cells have
been shown to improve the outcome of allogeneic stem-cell transplantation for leukemia.
In addition, in vivo transfer of NK cells may soon reveal an important therapeutic tool for
leukemia, if tolerance to NK-mediated anti-leukemia effects is overcome. This will require,
at a minimum, the ex vivo generation of a clinically safe NK cell product containing ade-
quate numbers of NK cells with robust anti-leukemia potential. Ideally, ex vivo generated
NK cells should also have similar anti-leukemia potential in different patients, and be easy to
obtain for convenient clinical scale-up. Moreover, optimal clinical protocols for NK therapy
in leukemia and other cancers are still lacking. These and other issues are being currently
addressed by multiple research groups. This review will first describe current laboratory
NK cell expansion and differentiation techniques by separately addressing different NK cell
sources. Subsequently, it will address the mechanisms known to be responsible for NK cell
alloreactivity, as well as their clinical impact in the hematopoietic stem cells transplantation
setting. Finally, it will briefly provide insight on past NK-based clinical trials.
Keywords: NK cells, NK-based immunotherapy, acute myeloid leukemia, NK cell expansion, hematopoietic stem
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INTRODUCTION
Natural killer (NK) cells play a key role in the immune response to
infections and malignancies by direct cytolysis of infected or trans-
formed cells and by secretion of potent immune mediators. NK cell
killing depends on the overall balance of inhibitory and activating
signaling mediated by an array of surface receptors recognizing
cognate ligands on putative targets. Besides their lytic activity, NK
cells are cytokine-producing cells. Several reports highlight the fact
that NK cells are also regulatory cells engaged in reciprocal inter-
actions with dendritic cells, macrophages, T cells, and endothelial
cells (1). NK cells have a central role in tumor-cell surveillance (2)
as demonstrated in the setting of allogeneic hematopoietic stem
cell transplantation (HSCT) (3–8).
Inhibitory NK receptors with specificity for HLA class I antigens
are well described. Among these, killer Ig-like receptors (KIR) bind
several HLA class I ligand groups (9), while the CD94–NKG2A/B
heterodimer recognizes HLA-E (10). Several activating receptors
are also described. Activating NKG2D is a major mediator of spon-
taneous cytotoxic activity. Natural cytotoxicity receptors (NCRs),
including three molecules (i.e., NKp46, NKp30, and NKp44) spe-
cific for mostly unknown ligands (11, 12), mediate cell lysis of
many cancer cells. Escape mechanisms from NK cell surveillance
may involve NK cell quantitative deficiency and NK cell functional
impairment.
Recent studies suggest that NK cell-based immunotherapy may
continue to be an effective approach for patients with leukemia
and emerging strategies are currently under investigation, initially
based on adoptive transfer of NK cells.
This review will first describe current laboratory NK cell expan-
sion and differentiation techniques by separately addressing differ-
ent NK cell sources. Subsequently, it will address the mechanisms
known to be responsible for NK cell alloreactivity.
NK CELL DIFFERENTIATION AND EXPANSION
NK CELL EXPANSION AND NK CELL GENERATION METHODS
Successful NK cell immunotherapies require an adequate number
of NK cells. In addition to NK cell number, NK cell purity and
function are key factors for a clinically efficacious NK cell product
(13). Various methods of NK cell expansion have been explored
(14). In general, NK cells can be produced from peripheral blood
(PB), umbilical cord blood (UCB), bone marrow (BM), embry-
onic stem cells (hESC), or induced pluripotent stem cells (iPCS).
While short-term NK cell culturing does not normally enhance the
functional capabilities for in vivo transferred NK cells, long-term
expansion methods may yield large numbers of functional NK
cells, which may potentially benefit cancer patients (15). Several
alternative protocols for NK cell ex vivo expansion for adoptive
immunotherapy have been reported to date. However, only some
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strategies have been developed under good manufacturing practice
(GMP) conditions. In addition, substantial variability in NK cell
expansion efficiency, phenotype, and function has been observed
among different protocols and among individual donors (16–20).
EXPANSION OF NK CELLS FOR CLINICAL PURPOSES ISOLATED FROM
PERIPHERAL BLOOD HUMAN
Several protocols for the expansion of PB NK cells are cur-
rently available, and others are under development. Various feeder
cell-based systems have been used for NK cell expansion from
peripheral blood mononuclear cells (PBMC), including third-
party Epstein–Barr virus transformed lymphoblastoid B cell lines
(EBV–BLCL), genetically modified K562 cells, or irradiated autol-
ogous cells (21–24). Ex vivo expansion of bulk peripheral NK
cells using third-party EBV–BLCL feeders approximately yields a
180-fold NK cell expansion after 2 weeks of culture (22). Another
expansion technique, yielding clinical valuable amounts of NK
cells, is based upon K562 cell feeder double-transduced with IL-15
and 4-1BB (CD137) co-stimulatory ligand (K562–mb15–41BBL)
(23). K562 cells transduced with IL-21 have also been used as
feeder cells in NK co-culture systems (25). While K562–mb15–
41BBL have been shown to expand and functionally enhance PB
NK cells, K562 genetically engineered with membrane-bound IL-
21 allow an even higher proliferation and cytotoxicity of expanded
NK cells, which also display longer telomeres and less senescence
(25). To expand CliniMACS-purified PB NK cells, autologous
irradiated feeder cells have also been used as feeder cells in cultur-
ing systems containing human serum, IL-2, IL-15, and anti-CD3
antibody (21).
Many PB NK expansion strategies hold promise for NK-based
immunotherapies. However, even using identical protocols, NK
cell expansion yields and purity are typically inconsistent, and
significant donor-to-donor variation is common. Moreover, com-
plete absence of any residual viable tumor feeder in all final cell
products is a critical requirement for large-scale NK cell therapy
applications and their pharmaceutical translation.
The type of disposable cell culture systems for NK cell culturing
also appears to influence the characteristics of the final cell prod-
uct. Currently used disposable cell culture systems include flasks,
bags, or WAVE® bioreactors. Compared to flasks, use of biore-
actors allow a 10-fold higher NK cell expansion after 3 weeks of
culture (26), at the expense of a reduced purity of the final prod-
uct, which also contains T cells (CD3+/CD56−) as well as NKT
cells (CD3+/CD56+). Presence of T cells limits the application
of this cell product to the autologous setting in the absence of
downstream T-cell depletion.
NK CELL GENERATION FROM UMBILICAL CORD BLOOD
Umbilical cord blood is thought to be an excellent source for cell
therapy applications. Initial work on positively selected cord blood
NK cells, cultured on a feeder layer of mesenchymal stromal cells
using a combination of IL-2, IL-15, Flt-3L, and IL-3, resulted in
a mere 60-fold median expansion (27). In consideration of the
low starting NK cell number in standard cord blood units, this
approach is not feasible to generate NK cell numbers needed for a
therapeutic NK cell product. Additionally, NK cell differentiation
from CD34+ hematopoietic stem cells (HSC) has been addressed
(28). Initially, research in this field focused on the ex vivo gener-
ation of NK cells from BM CD34+ cells (29–33), but later also
involved CD34+ cells derived from UCB (34–39), a particularly
rich source of HSC. These studies used different combinations of
growth factor and cytokine mixtures, BM stroma cells, and culture
media with or without animal or human sera. These culture sys-
tems generally contain components of animal origin; moreover,
they fail to yield significant numbers of mature NK cells. For these
reasons, it is unlikely that they will be used for clinical applica-
tions. Interestingly, the system reported by Silva et al. contained
human serum without stroma cells and was therefore favored for
clinical scaling-up (40). This NK cell expansion method was later
abandoned, once stroma cells were recognized as a potential criti-
cal component for the enhancement of NK cell proliferation (40).
In 2007, Kao et al. showed that serum-free expanded CD34+ cells
may be differentiated into a NK cell product with an average purity
of 40–60% after 5–7 weeks of culture, with a mean expansion rate
of 300-fold. Such expansion, however, was obtained in the pres-
ence of fetal bovine serum (41). Later on, Vitale et al. studied
the effects of methylprednisolone on CD34+ precursor cells and
their ability to differentiate toward NK cells (38). They performed
direct NK cell differentiation – i.e., no upfront CD34+ expansion –
using RPMI-1640 medium supplemented with human serum, fetal
bovine serum, and a cytokine cocktail including IL-15 and IL-21.
At day 25, they observed a 10-fold NK cell expansion, with an
average purity of approximately 30%.
In 2010, a novel cell culture technology for the ex vivo expan-
sion and NK differentiation of UCB-derived CD34+ cells was
developed. This technique was based upon a clinical-grade serum-
free culture medium and a mixture of heparin and cytokines, in
order to mimic the extra-cellular matrix BM microenvironment
in the absence of feeder cells (42). This method yielded up to
1010 CD34+ cell-derived NK cells, generated in static cell culture
bags and automated bioreactors. Importantly, NK cell products
were not found to be contaminated by T cells, and may there-
fore be safely used in the allogeneic setting (43). Additionally, NK
cells expressed high levels of activating receptors (e.g., NKG2D
and NCR), and are able to efficiently kill myeloid leukemia and
melanoma cell lines, as well as primary leukemia blasts. Further-
more, mouse studies have shown that they expand in vivo, initially
home to the lung, and later to the blood, lung, spleen, liver, and BM
and prevent outgrowth of local tumors in the BM (44). A phase I
trial in elderly acute myeloid leukemia (AML) patients using NK
cell products based upon this expansion technique is currently
in progress (CCMO nr. NL31699 and Dutch Trial Register nr.
2818) (43).
Definitely,producing NK cells from CD34+hematopoietic pre-
cursors can be practically advantageous, since stem cells can be
isolated and frozen, and can overcome several obstacles posed by
purified PB NK cells (15).
NK CELL GENERATION FROM HUMAN EMBRYONIC STEM CELLS OR
INDUCED PLURIPOTENT STEM CELLS
In contrast to the CD34+ UCB-derived NK cells, the generation
of NK cells from embryonic stem cells or induced pluripotent
stem cells is to date largely experimental (45). As previously men-
tioned, human NK cells can be differentiated from CD34+ HSC
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under certain culture conditions (31, 35, 42). Currently, optimiz-
ing the generation of CD34+ HSC from hESC and iPSC remains
a major challenge to rationally approach hESC- and iPSCs-based
NK cell therapy (45–48). hESCs or iPSCs derived CD34+ cells
are known to be enriched for hematopoietic progenitors defined
by colony-forming cells, which could serve as a suitable source
for cell therapy (47). Some years ago, a method for the efficient
generation of functional NK cells from hESC using a two-step pro-
cedure was described. NK cell products contained cytotoxic cells,
displayed a mature NK cell phenotype, including CD16 and KIR,
CD94/NKG2A, NKp46, NKp44, NKG2D, TRAIL, and FasL (49).
Engineering CD34+ cells, hESCs, or iPSCs to express chimeric
antigen receptors (CAR) specific for tumor-associated antigens is
a potentially promising immunotherapeutic strategy (48).
NK CELL LINES FOR CLINICAL USE
Several authors have reported on the use of NK cell lines for ther-
apeutic purposes. Unlike primary NK cells, whose in vivo life span
is limited, NK cell lines are immortal. However, most NK lines are
weakly cytotoxic to cancer targets. Conversely, the NK-92 cell line
(Neukoplast, Conkwest, San Diego) has shown to mediate liable
cytotoxicity and good expansion kinetics when cultured in bags
or bioreactors. NK-92 has been well characterized in in vitro and
shown to display remarkable anti-tumor activity in severe com-
bined immunodeficiency (SCID) mouse xenotransplant models
(50). Furthermore, it has been extensively tested in the clinical
setting (51).
ALTERATION OF NK-MEDIATED CYTOTOXIC RESPONSE
AGAINST LEUKEMIA
The escape of hematological malignancies from NK cell immunity
can be explained by general mechanisms involving the quantita-
tive deficiency of NK cells, their qualitative impairments caused
by increased inhibition, decreased activation signaling, or by the
negative influence of tumor microenvironment. It is widely rec-
ognized that leukemia cells may oppose a variety of immune
escape strategies, including immune suppression and phenotypic
mimicry, to elude NK-mediated killing.
The balance between activating and inhibitory signals received
by NK cells will determine the NK cell-mediated elimination of
leukemia cells. Decrease in ligands for activating receptors on
leukemia cells could abolish NK cell dependent cytotoxicity. Fur-
thermore, interaction of other ligands with cognate inhibitory
receptors on NK cells surface could diminish NK cell killing activ-
ity, granule mobilization, and interferon production. Accumulat-
ing evidence indicates that chronic and acute leukemia cells could
modulate NK cell activity by secreting soluble and exosomal lig-
ands for NK cell receptors (52, 53). A key strategy used by leukemia
cells to escape elimination by NK cells is related to apoptosis,
and altered expression of molecules involved in different apop-
tosis signaling pathways may result in resistance to NK-mediated
killing (54–56). In this setting, deregulation of the mitochon-
drial apoptotic machinery, functional blocks of caspase cascade,
downregulation or inactivation of proapoptotic molecules, and
upregulation of antiapoptotic molecules may all potentially favor
leukemia chemoresistance or relapse. Finally, mechanism of NK
cell resistance may also include drug resistance. For example, it has
been shown that doxorubicin resistant cells increase expression of
HLA class I on their surface (57).
CAPTURING NK CELL ALLOREACTIVITY IN HEMATOPOIETIC
STEM CELL TRANSPLANTATION
In the last 15 years, growing knowledge of NK tolerance to self,
cancer immunosurveillance, and functional licensing has been
extensively applied to HCT, in an effort to identify donors pro-
tecting from leukemia relapse through NK-based alloreactivity.
Most studies investigating NK effects on transplantation outcome
are rationally based upon one of the following three models: the
missing-self recognition paradigm, the missing ligand model, and
the activating receptor-based NK cell alloreactivity. This section
addresses the mechanisms known to be responsible for NK cell
alloreactivity, as well as their clinical impact in the HSCT.
RECOGNITION OF HLA CLASS I ANTIGENS BY KILLER
IMMUNOGLOBULIN-LIKE RECEPTORS
The KIR gene cluster is mapped on chromosome 19q13.4, within
the 1 Mb leukocyte receptor complex (LRC). It contains four
ubiquitous “framework” genes (one centromeric, KIR3DL3; one
telomeric, KIR3DL2; and two central, KIR3DP1 and KIR2DL4)
that flank centromeric and telomeric gene motifs characterized by
extensive variation in both gene content (type and number) and
polymorphism (58–60). Based on KIR gene content, multiple KIR
haplotypes are identified, and categorized into two distinct groups,
A and B. Group A haplotypes contain genes exclusively encoding
inhibitory receptors and the activating KIR2DS4, while group B
haplotypes contain genes encoding both inhibitory and activat-
ing receptors. Both KIR A and B haplotypes possess centromeric
and telomeric gene content motifs. Products of functional KIR
genes are type I transmembrane receptors with two (KIR2D) or
three (KIR3D) highly homologous, extra-cellular immunoglobu-
lin domains (61, 62, 63). Due to their clonal distribution in the
NK repertoire, an individual NK cell may express one or more
KIR (64, 65).
Inhibitory KIR may recruit the SH2-domain-containing tyro-
sine phosphatase 1 protein (SHP1) (66–69) through a single or
double immunoreceptor tyrosine-based inhibitory motif (ITIM)
contained in their long cytoplasmic tail (denoted L, i.e., KIR2DL;
KIR3DL). Of several known inhibitory KIR, 2DL1, 2DL2, 2DL3,
and 3DL1 are particularly relevant for HLA class I recognition.
KIR2DL1 is specific for HLA-C2 group antigens (sharing the
Asn77/Lys80 residues in the HLA-Cw heavy chain); KIR2DL2 and
KIR2DL3 are specific for HLA-C1 group antigens (sharing the
Ser77/Asn80 in the HLA-Cw heavy chain) (70, 71); and KIR3DL1 is
specific for HLA-Bw4 ligands, sharing a group of sequence motifs
in residues 77–83 of the heavy chain of certain HLA-B and HLA-A
alleles (72–74).
Killer Ig-like receptor mediated activating signaling has also
been identified. Unlike inhibitory KIR, they possess truncated
portions that transduce activating signals via tyrosine phosphory-
lation of DAP12 and other proteins (75–77). Couples of cognate
activating and inhibitory KIR, sharing almost complete homology
(95–99%) in their extra-cellular domains, are recognized (75).
Thus, activating KIR2DS1, KIR2DS2, and KIR3DS1 are, respec-
tively, cognate receptors for the HLA class I-specific inhibitory
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KIR2DL1, KIR2DL2, and KIR3DL1. Counter-intuitively, the iden-
tification of natural ligands for activating receptors remains largely
elusive. Ligands for activating KIR2DS2 and KIR3DS1 receptors
have not been identified. While it cannot be excluded that these
receptors recognize HLA class I/peptide complexes, current evi-
dence indicates that they may not affect NK function by generating
activating signaling when HLA-C1 and HLA-Bw4 are self-ligands.
Unique among activating KIR, 2DS1 recognizes HLA-C2 group
antigens, similar to its inhibitory homolog 2DL1.
THE MISSING-SELF RECOGNITION PARADIGM AND NK CELL
ALLOREACTIVITY
Inhibitory KIR interactions with cognate HLA class I ligands play
a critical role in NK cell education and tolerance to self. In normal
individuals, NK cells commonly possess KIR repertoires including
one or more KIR with ligand specificity for self-HLA class I ligands
(65). It is generally believed that such NK cells are rendered func-
tionally competent, or licensed, by continuous signaling generated
by inhibitory KIR upon interaction with self-HLA class I antigens
(78, 79). HLA class I is critical to maintain NK tolerance to self,
and cells failing to express sufficient levels of HLA class I ligands
are promptly cleared by NK-mediated cytotoxicity. This phenom-
enon, known as missing-self recognition, was first postulated in
a report by Kärre et al. describing that lack of MHC class I (H2)
antigen expression rendered mice lymphoma cells highly sensitive
to NK-mediated rejection (80).
Natural killer cells from donor-derived hematopoietic progen-
itor cells quickly reconstitute in HCT recipients (81–83). In the
HSCT setting, HLA class I ligands of donor origin are believed to
drive functional licensing. Reconstituted NK cells expressing one
KIR for HLA class I present in the donor display stronger in vitro
responsiveness than NK cells expressing one KIR for HLA class I
present in the recipient, but absent in the donor (84). Additionally,
CD107a externalization and IFNg production of NK cells reconsti-
tuting in recipients of donor unrelated or UCB grafts is markedly
increased if they express KIR for donor self (85). This donor HLA-
based NK education model implies, that the size of licensed donor
NK cell is shaped by the frequency of inhibitory KIR-positive NK
cells combined with the presence of cognate HLA class I ligands
in the donor. Thus, KIR2DL1+ NK cells would acquire functional
competence if donor is HLA-C2; KIR2DL2–3+ NK cells if donor
is HLA-C1; and KIR3DL1+ NK cells if donor is positive for HLA-A
or -B alleles possessing the Bw4 motif.
In HLA-mismatched HSCT, HLA-C allele groups (C1 or C2),
and/or the Bw4 epitope may be present in the donor and absent
in the recipient. In this situation, the repertoire of licensed donor
NK cells may include NK clones mediating missing-self allorecog-
nition against host tissues. For example, KIR2DL1+/KIR2DL2–
3−/KIR3DL1− clones from a HLA-C2 positive donor may display
allorecognition of missing self in a HLA-C2 negative recipient.
Recognition of missing self-HLA class I may improve the out-
come of HSCT. T-cell-depleted haplotype-mismatched grafts from
NK alloreactive donors mediate strong graft vs. leukemia (GvL)
effects in AML recipients, allowing for lower risk of relapse and
better survival (3, 4). While in haplotype-mismatched grafts, the
effect of KIR-ligand incompatibility is well established, studies
on mismatched unrelated HSCT reported conflicting results. In
this setting, Giebel et al. showed that donor NK cell alloreactivity
improves recipient survival (86). A protective effect of KIR-ligand
incompatibility on post-transplantation relapse was later con-
firmed in myeloid malignancies (87) and multiple myeloma (88).
However, most studies failed to show a beneficial effect of donor
NK cell alloreactivity on the outcome of mismatched unrelated
HSCT (89–92). Similarly, studies exploring the clinical impact of
NK alloreactivity mediated by KIR-ligand mismatch in UCB grafts
have yielded variable results (93, 94). These inconsistent observa-
tions are possibly influenced by complex variables, such as donor
KIR genotype (95), disease category, type of conditioning T-cell
depletion, post-transplantation immune suppression for graft vs.
host disease (GvHD) prophylaxis. For example, T cells may domi-
nate alloreactive phenomena in mismatched unrelated HSCT and
counteract the clinical benefit of NK alloreactivity (91). Accord-
ingly, in vivo T-cell depletion with anti-thymocyte globulin (ATG)
has been shown (86, 88, 96) to enhance the favorable impact of
NK cell alloreactivity on HSCT outcome.
THE MISSING LIGAND MODEL AND NK CELL ALLOREACTIVITY
Killer Ig-like receptors and HLA genes are mapped on differ-
ent chromosomes, and segregate independently according to a
Mendelian inheritance pattern. Therefore, certain individuals may
have KIR genes but not the corresponding HLA/KIR-ligand groups
(97). KIR receptors are clonally distributed on NK cell surface,
allowing for the possibility, that subpopulations of NK cells exclu-
sively express KIR with ligand specificity for non-self-HLA class I
ligands. These NK cells are not classically licensed by self-HLA class
I ligands during their development, and are believed to be hypore-
sponsive to stimulation in physiologic conditions. During post-
transplant immune reconstitution, however, this non-licensed
status may be transiently suspended during post-transplantation
immune reconstitution, and effector functions could indeed be
mediated by donor NK cells expressing KIR with ligand specificity
for non-self-HLA class I. An important implication of the missing
ligand model is that NK alloreactivity would be observed even in
the absence of donor/recipient KIR-ligand mismatch, a necessary
condition for missing self-mediated NK alloreactivity.
Several studies exploring the effect of the missing ligand model
on HSCT outcome indicate, that donors possessing inhibitory KIR
but not the corresponding HLA class I ligand do mediate beneficial
NK effects in HLA-identical siblings or HLA-matched unrelated
recipients (5,98–100). Hsu et al. originally explored a cohort of 178
subjects receiving a T-cell-depleted graft from a HLA-identical sib-
ling. In patients with AML and myelodysplastic syndromes (MDS),
lack of one or more HLA ligand for donor KIR resulted in lower
relapse and better survival (5). Following the identification of ben-
eficial NK effects in the HLA-matched setting, the function of
classically non-licensed NK cells has been directly explored in the
context of post-transplantation reconstitution. In T-cell-depleted
grafts from HLA-identical siblings, NK cells expressing KIR for
non-self-HLA display strong IFNγ production and cytotoxicity to
target stimulation during the first trimester post-transplantation
(101). These findings have not been confirmed in a cohort of recip-
ients of T cell-replete grafts from HLA-identical siblings. Here,
reconstituted NK cells expressing KIR for non-self-HLA ligands
displayed tolerance to self. Moreover, lack of self-HLA ligands
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for donor inhibitory KIR was found to have no effect on HSCT
outcome (102). Presence or absence of T cells in the graft may
differentially affect self-tolerance of non-licensed donor NK cells
post-transplantation. Regardless, the interpretation of these con-
flicting results demands further studies on tolerance to self of
donor NK cells reconstituting in the HLA-identical host.
ACTIVATING RECEPTOR-BASED NK CELL ALLOREACTIVITY
Because ligands for most activating KIR are currently unknown,
studies reporting associations between activating KIR and HSCT
outcome are not generally supported by the identification of an
underlying immunological background mechanistically explain-
ing the observed NK-mediated alloreactivity. In a cohort of 65 graft
recipients from HLA-identical siblings, donors with genotypes
containing both KIR2DS1 and KIR2DS2 genes provided protec-
tion from relapse (103). Donor activating KIR was later found
to control CMV reactivation post-transplantation. Recipients of
T cell-replete grafts were found to have a remarkable reduction
of the incidence of CMV reactivation, if donor possessed more
than one activating KIR genes (104). Confirmation of the protec-
tive effect against CMV reactivation by donor activating KIR was
concomitantly reported by another group (105).
In 2009, Cooley et al. investigated the effect of different donor
KIR haplotypes in 448 AML recipients of unrelated T cell-replete
HSCT. Recipients of KIR B/x grafts (i.e., homozygous or heterozy-
gous for KIR B group haplotypes) displayed a higher 3-year-overall
survival (6). In a cohort of 1086 AML recipients of unrelated grafts,
the same group later compared the contribution to HSCT out-
come of donor centromeric and telomeric group A and B KIR
haplotypes. Donors homozygous for centromeric B gene content
motifs (Cen B/B) most strongly associated with low risk of relapse
and prolonged survival (7). Among activating KIR, activating
KIR2DS2 is mapped on the centromeric region of several B group
haplotypes, and may thus mediate the clinical benefit observed
for Cen B/B donors through interaction with an unknown ligand
expressed on leukemia cells (7).
Recent studies investigated the effect of telomeric activat-
ing KIR3DS1 and KIR2DS1 genes on transplantation outcome.
Patients receiving unrelated grafts from KIR3DS1 donors exhib-
ited a lower risk for grade II–IV GvHD and mortality (8, 106).
Activating KIR2DS1 is found in approximately 1/3 Caucasians,
and commonly occurs in individuals positive for HLA-C2 (C1/C2;
C2/C2) (107–109). KIR2DS1 expression occurs in more than 20%
NK cells (109), and 2DS1 single positive (KIR2DS1SP) NK cells
(i.e., lacking inhibitory KIR expression), may also be identified. In
HLA-C2 individuals, KIR2DS1SP NK cells may potentially display
auto-reactivity to normal self-tissues. Compared with HLA-C1
donors, KIR2DS1SP NK cells from HLA-C2 homozygous indi-
viduals are hyporesponsive to a HLA-C2 positive target cell (108).
Similarly, mice studies described hyporesponsiveness of activating
receptor-positive NK cells resulting from in vivo chronic interac-
tion with a viral ligand (110, 111). Recently, KIR2DS1SP NK clones
displaying in vitro anti-HLA-C2 cytotoxicity have been identified
in all HLA-C genotypes (112). In C2:C2 individuals, these clones
are significantly reduced in frequency. In contrast, anti-HLA-C2
reactive KIR2DS1SP clones from C1:C2 individuals are common,
and functionally indistinguishable to those obtained from HLA-C2
negative (C1:C1) donors (112). These observations indicate that
tolerance development is affected by HLA-C2 ligand expression
density, and are consistent with the “functional NK plasticity”
phenomenon described in mice studies (113, 114). The effect of
donor KIR2DS1 on HSCT outcome has been assessed in a cohort
of 1277 AML recipients of unrelated HLA-matched or 9/10 mis-
matched HSCT. Patients receiving grafts from KIR2DS1 donors
displayed a decreased rate of leukemia relapse (8). In agreement
with experimental findings (112), KIR2DS1-mediated protection
was observed in HLA-C1 (C1:C1 and C1:C2) donors, but not
in HLA-C2 homozygous donors, presumably due to the strong
tolerogenic effect on KIR2DS1-positive NK cells mediated by the
HLA-C2 homozygous genotype (8).
NK CELL THERAPY MODALITIES
Early studies by Miller et al. in 2005 have open the way to demon-
strate the safety of adoptive transferred human NK cells in patients
with AML. Human haplo-identical NK cells could be expanded
in vivo and transferred in patients with poor prognosis AML.
Patients had to be prepared with an immunosuppressive high
dose alkylating and purine analog conditioning regimen they
can promote recirculation of infused allogeneic NK cells. Fur-
ther haplo-identical allogeneic NK cells infusions were applied
in patients with poor prognosis Hodgkin lymphoma and various
solid tumors, i.e., melanoma (115) and renal cell carcinoma. In
order to promote NK cell expansion, a lympho-depletion prepar-
ative regimen is required for the patient in all studies reported.
To date, adoptive immunotherapy with unstimulated or IL-2 acti-
vated NK donor NK cells infusion is used for patients undergoing
haplo-identical hematopoietic progenitor cells transplantation to
prevent from relapse. No serious and immediate adverse effects
have been observed following allogeneic NK cells infusion.
Clinical scale protocols to collect, enrich, and expand purified
NK cells are nowadays feasible from cord blood, human donor
apheresis, and dedicated cell lines. These cell therapy procedures
remain costly and time consuming. They need an experimental
lab with GMP facilities together with the skills and allowance to
perform the cell manipulation.
The currently defined cell product has optimized T-cell deple-
tion to avoid GvHD and allogeneic NK cell expansion; but we
are still lacking a clinical standardized procedure for the use of
enriched and expanded NK cells (116).
The most common limitation of the procedure remains the
inability of collected, enriched, activated, and expanded allogeneic
NK cells to expand properly in vivo. At first, a huge loss of NK cells
during the isolation procedure can be seen following T-cell deple-
tion procedure. Then CD56+/CD3− NK cells may be rejected by
cytotoxic T cells or suppressed by myeloid-derived suppressor cells
or Tregs.
To date, ongoing clinical scale protocols aim to both select
CD56+/CD3− NK cells and increase drastically the total num-
ber of NK cells. Another limitation comes from the use of high
dose alkylating chemotherapy-based protocols prior to infusion
of NK cells that can increase the toxicity and efficacy of NK
cell-based immunotherapy. Infusion of allogeneic NK cells can
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be performed following standard doses regimen together with
immune modulation with steroids and IL-15.
In the field of BM transplantation, infusion of donor-derived
stimulated and expanded CD56+/CD3− allogeneic NK cells may
be used in repetitive injections to promote the GvL effect. Fur-
ther studies have to be designed to enhance the NK cell therapy
efficiency: improving the NK cell selection, processing, ex vivo
expansion, better designing of lympho-depletion protocols for the
patient and infusion rate of NK cells for a optimized control of
residual leukemic cells.
CONCLUSION
Natural killer cells continue to attract a lot of interest in transplan-
tation. However defects in NK cell cytotoxicity have been observed
in all hematological malignancies and the escape of hematological
malignancies from NK cell immunity can be explained by gen-
eral mechanisms. The latter are common to all immune-effector
cells involving the quantitative deficiency of NK cells, their qual-
itative impairments caused by increased inhibition, or decreased
activation signaling.
Natural killer cell selection from leukapheretic products is a
largely inadequate approach to obtain large numbers of cancer-
reactive NK cells. Given the clonal and stochastic distribution
of activating and inhibitory receptors on NK cell surface, pools
of cancer-reactive NK cells generally represent a minority of the
bulk CD3−, CD56+ population. Several methods for ex vivo NK
cell expansion have been attempted to date. However, none of
the described approaches have definitively proved able to effec-
tively circumvent the issue of limited NK cell availability and
efficiency. Although an important anti-tumor role for alloreac-
tive NK cells has been shown in patients with AML either after
stem-cell transplantation or adoptive transfer of haplo-identical
NK cells, their clinical efficacy in human trials has been mod-
est, presumably due to tumor escape by alteration of NK cell
function and resistance to killing. In this respect, the ability to
manipulate not only the balance of activating and inhibitory
receptors on NK cells but also their cognate ligands, as well as
the sensitivity of tumor cells to apoptosis, opens new perspec-
tives in NK cell-based immunotherapy. Sensitization of tumor
cells to activated cytotoxic lymphocytes by up-regulating either
TNF death receptors or effector-activating ligands on tumor
cells combined with immunotherapy has been pursued to over-
come tumor-cell resistance and establishes an effective anti-tumor
response. Another therapeutic approach to enhance NK cell cyto-
toxicity is the use of cytokines, such as IL-2, IL-12, and IL-18.
Chemokine manipulation is also of interest as molecules may
both attract NK to the tumor-cell microenvironment and stim-
ulate their cytotoxic properties. Another attractive approach to
enhance NK cytotoxicity is to use monoclonal antibodies (mAbs).
IPH-2101, a fully human IgG4 anti-KIR mAb (developed by
Innate Pharma) is currently being tested in phase I and II clin-
ical trials in patients with AML and multiple myeloma (117).
Its blockade of inhibition could allow NK cell activation when
activating ligands are present on target cells. It should also be
emphasized that bispecific mAbs directed against both the target
cells and NK cells are also currently under investigation. Anti-
CD20 mAbs that have enhanced affinity for CD16 have been
also developed, and they are more effective at NK activation than
rituximab (118).
One limitation of the use of NK cells is due to the great capac-
ity of leukemic cells to escape to NK recognition and killing.
This resistance remains indeed a drawback in immunotherapy
of hematological malignancies. In this regard, adoptive transfer of
polyclonal or clonal NK cells with mismatch NK inhibitory recep-
tors and HLA class I ligands would produce GvL (GvHD) in the
absence of GvHD. The simultaneous differentiation of the effective
killer effectors, the boosting of NK function, their expansion, and
the sensitization of leukemic targets will offer potential opportu-
nities in the treatment of hematological malignancies. Therefore,
how to expand UCB stem cells for optimal downstream genera-
tion of terminally differentiated NK cells potentially alloreactive
to leukemic cells is at present very challenging.
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